Diseases originating from altered protein quality control in the endoplasmic reticulum

Mieko Otsu, Roberto Sitia

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

A challenging question in biology is how cells control their shape and volume. The relative abundance of organelles can be radically modified to comply with a new task, an example being the massive development of the endoplasmic reticulum (ER) in Ig-secreting plasma cells. The ER is the site where secretory proteins are made and folded. Remarkably, it can discriminate between native and non-native proteins, restricting transport to the former, whilst retaining and eventually degrading the latter (quality control). Recent studies revealed that certain components of the unfolded protein response (UPR), a multidimensional signalling pathway originally discovered in cells exposed to severe ER stress, are crucial for the normal development of secretory cells. According to the cell types, different arms of the UPR are required: the IRE1-XBP1 pathway is essential for plasma cell differentiation, whilst the PERK-eIF2α pathway is essential for pancreatic β cells survival. Therefore, the UPR is far from being a monolithic response. Disturbances in the signalling pathways that allow the ER to satisfy the changing demand of protein synthesis can occur at various levels and often cause diseases. Here we summarize the molecular mechanisms underlying this variegated and constantly growing class of pathological conditions, focusing on diseases that are linked to alterations in the quality control functions that the ER exerts over its protein products.

Original languageEnglish
Pages (from-to)1639-1652
Number of pages14
JournalCurrent Medicinal Chemistry
Volume14
Issue number15
DOIs
Publication statusPublished - Jun 2007

Fingerprint

Unfolded Protein Response
Endoplasmic Reticulum
Quality Control
Quality control
Plasma Cells
Proteins
Endoplasmic Reticulum Stress
Protein Transport
Organelles
Cell Biology
Cell Differentiation
Cell Survival
Plasmas
Cells

Keywords

  • Aggregation
  • Endoplasmic reticulum
  • ER proliferation
  • ER storage disease
  • ERAD
  • Quality control
  • Transport
  • UPR

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Organic Chemistry
  • Pharmacology

Cite this

Diseases originating from altered protein quality control in the endoplasmic reticulum. / Otsu, Mieko; Sitia, Roberto.

In: Current Medicinal Chemistry, Vol. 14, No. 15, 06.2007, p. 1639-1652.

Research output: Contribution to journalArticle

@article{e587b3d52f494ed08132111f398fcd98,
title = "Diseases originating from altered protein quality control in the endoplasmic reticulum",
abstract = "A challenging question in biology is how cells control their shape and volume. The relative abundance of organelles can be radically modified to comply with a new task, an example being the massive development of the endoplasmic reticulum (ER) in Ig-secreting plasma cells. The ER is the site where secretory proteins are made and folded. Remarkably, it can discriminate between native and non-native proteins, restricting transport to the former, whilst retaining and eventually degrading the latter (quality control). Recent studies revealed that certain components of the unfolded protein response (UPR), a multidimensional signalling pathway originally discovered in cells exposed to severe ER stress, are crucial for the normal development of secretory cells. According to the cell types, different arms of the UPR are required: the IRE1-XBP1 pathway is essential for plasma cell differentiation, whilst the PERK-eIF2α pathway is essential for pancreatic β cells survival. Therefore, the UPR is far from being a monolithic response. Disturbances in the signalling pathways that allow the ER to satisfy the changing demand of protein synthesis can occur at various levels and often cause diseases. Here we summarize the molecular mechanisms underlying this variegated and constantly growing class of pathological conditions, focusing on diseases that are linked to alterations in the quality control functions that the ER exerts over its protein products.",
keywords = "Aggregation, Endoplasmic reticulum, ER proliferation, ER storage disease, ERAD, Quality control, Transport, UPR",
author = "Mieko Otsu and Roberto Sitia",
year = "2007",
month = "6",
doi = "10.2174/092986707780830952",
language = "English",
volume = "14",
pages = "1639--1652",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "15",

}

TY - JOUR

T1 - Diseases originating from altered protein quality control in the endoplasmic reticulum

AU - Otsu, Mieko

AU - Sitia, Roberto

PY - 2007/6

Y1 - 2007/6

N2 - A challenging question in biology is how cells control their shape and volume. The relative abundance of organelles can be radically modified to comply with a new task, an example being the massive development of the endoplasmic reticulum (ER) in Ig-secreting plasma cells. The ER is the site where secretory proteins are made and folded. Remarkably, it can discriminate between native and non-native proteins, restricting transport to the former, whilst retaining and eventually degrading the latter (quality control). Recent studies revealed that certain components of the unfolded protein response (UPR), a multidimensional signalling pathway originally discovered in cells exposed to severe ER stress, are crucial for the normal development of secretory cells. According to the cell types, different arms of the UPR are required: the IRE1-XBP1 pathway is essential for plasma cell differentiation, whilst the PERK-eIF2α pathway is essential for pancreatic β cells survival. Therefore, the UPR is far from being a monolithic response. Disturbances in the signalling pathways that allow the ER to satisfy the changing demand of protein synthesis can occur at various levels and often cause diseases. Here we summarize the molecular mechanisms underlying this variegated and constantly growing class of pathological conditions, focusing on diseases that are linked to alterations in the quality control functions that the ER exerts over its protein products.

AB - A challenging question in biology is how cells control their shape and volume. The relative abundance of organelles can be radically modified to comply with a new task, an example being the massive development of the endoplasmic reticulum (ER) in Ig-secreting plasma cells. The ER is the site where secretory proteins are made and folded. Remarkably, it can discriminate between native and non-native proteins, restricting transport to the former, whilst retaining and eventually degrading the latter (quality control). Recent studies revealed that certain components of the unfolded protein response (UPR), a multidimensional signalling pathway originally discovered in cells exposed to severe ER stress, are crucial for the normal development of secretory cells. According to the cell types, different arms of the UPR are required: the IRE1-XBP1 pathway is essential for plasma cell differentiation, whilst the PERK-eIF2α pathway is essential for pancreatic β cells survival. Therefore, the UPR is far from being a monolithic response. Disturbances in the signalling pathways that allow the ER to satisfy the changing demand of protein synthesis can occur at various levels and often cause diseases. Here we summarize the molecular mechanisms underlying this variegated and constantly growing class of pathological conditions, focusing on diseases that are linked to alterations in the quality control functions that the ER exerts over its protein products.

KW - Aggregation

KW - Endoplasmic reticulum

KW - ER proliferation

KW - ER storage disease

KW - ERAD

KW - Quality control

KW - Transport

KW - UPR

UR - http://www.scopus.com/inward/record.url?scp=34347355500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347355500&partnerID=8YFLogxK

U2 - 10.2174/092986707780830952

DO - 10.2174/092986707780830952

M3 - Article

C2 - 17584070

AN - SCOPUS:34347355500

VL - 14

SP - 1639

EP - 1652

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 15

ER -